Any current/future capex/capital investment/strategic investment?

Ongoing CAPEX of $100 million in synthesis expected to be reasonably utilized by mid of next financial year (FY25). Majority of FY24 CAPEX focused on synthesis and bio divisions, with expansion projects on track to support future growth. New capacity additions include 3 million liters of capacity and 5 billion tablets capacity in last three years. Groundbreaking of Unit-7 in Vizag to add more capacity for CDMO with common infrastructure. Creating common infrastructure and additional blocks at two sites to get regulatory approvals for servicing big pharma. ImmunoACT is creating a facility ready

Future growth expectations in sales/revenue/volumes?

Revenue growth seen with 14% increase in underlying business for H1 FY24; Q2 growth at 18%. Positive outlook for second half of FY24 and FY25, driven by increased sales across API (ARV, oncology, non-ARV), formulations, and CDMO segments. Oncology API sales rebounded strongly with over 50% growth in H1 FY24; order book strong beyond Q4. Non-ARV formulations growing, expected to be future growth driver as ARV market plateaus. CDMO expected to improve with new facilities coming online mid-FY25; animal health and agrochemical projects scaling up. New contract manufacturing deals and new

Future growth expectations in earnings/operating earnings/profits/EPS?

The company expects growth in revenues driven by new US approvals, new contract manufacturing deals in APIs and formulations, as well as growth in oncology and non-ARV, non-onco API sales. CDMO segment anticipated to regain strength with some projects moving into late clinical or commercial phase by next year (FY25/FY26). EBITDA margin target is around 30% in the medium term, though no specific timeline is provided. Near term (FY24) seen as a year of consolidation with expected flat to modest improvement in margins (EBITDA expected to improve beyond 15%, potentially towards 20%). Capac

Current/ Expected Orderbook/ Pending Orders?

Laurus Labs currently has 62 active projects in its CDMO pipeline. Out of these, 10 projects are commercial products (including APIs and advanced intermediates). The remaining 60 projects are at various clinical stages (Phase II, Phase III). The company mentioned a strong order book for H2 FY24, especially in the oncology API segment. New CMO orders have been tied up and are expected to start ramping up, mainly in the second half of the fiscal year. CDMO capacity expansions (including a new Unit-7 for CDMO) are ongoing to support increased order fulfillment. The company is optimistic about ord

Any current/future new fundraising through debt or equity?

There is no explicit mention of any current or future fundraising through debt or equity in the provided transcript. The company is investing significantly in CAPEX, particularly in synthesis and bio divisions, with around Rs.182 crores invested in the quarter and Rs.385 crores in H1 FY24. CAPEX is mostly funded internally as no details about fresh fundraises via debt or equity were disclosed. Management indicated focus on cautious investment and strong capital deployment for future growth, but no intention or plan for raising new funds through debt or equity was shared. The company highlighte

IN US

Sale is live|00:00:00left today

Laurus Labs LtdQ3 FY23Pharmaceuticals & Biotechnology

Laurus Labs Ltd Q3 FY23 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹1,450P/E: 80.4Market Cap: ₹71.5K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 1

Fundraise

N/A

Order

Yes

Capex

Yes

3 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 3

→Revenue growth seen with 14% increase in underlying business for H1 FY24; Q2 growth at 18%.
→Positive outlook for second half of FY24 and FY25, driven by increased sales across API (ARV, oncology, non-ARV), formulations, and CDMO segments.
→Oncology API sales rebounded strongly with over 50% growth in H1 FY24; order book strong beyond Q4.
→Non-ARV formulations growing, expected to be future growth driver as ARV market plateaus.
→CDMO expected to improve with new facilities coming online mid-FY25; animal health and agrochemical projects scaling up.
→New contract manufacturing deals and new product approvals in multiple markets (US, Canada, EU) support broad-based growth.
→FDF business recovering with better utilization of capacity expected by end FY24.
→EBITDA margins expected to improve towards 25-30% range as new capacities commercialize and revenue mix grows.

Margin guidance

Category 1

→The company expects growth in revenues driven by new US approvals, new contract manufacturing deals in APIs and formulations, as well as growth in oncology and non-ARV, non-onco API sales.
→CDMO segment anticipated to regain strength with some projects moving into late clinical or commercial phase by next year (FY25/FY26).
→EBITDA margin target is around 30% in the medium term, though no specific timeline is provided.
→Near term (FY24) seen as a year of consolidation with expected flat to modest improvement in margins (EBITDA expected to improve beyond 15%, potentially towards 20%).
→Capacities added in recent years (3 million liters and 5 billion tablets) expected to become fully utilized from FY25, driving leverage and improved margins.
→Sequential momentum and order book strength especially in oncology and CDMO support optimism for second half FY24 and beyond.
→EPS showed recovery (Q2 EPS 0.6, H1 EPS 1.1) with cautious but positive outlook for improving profitability.

3 more insights locked — sign up free to unlock

Fundraise plans

→There is no explicit mention of any current or future fundraising through debt or equity in the provided transcript.
→The company is investing significantly in CAPEX, particularly in synthesis and bio divisions, with around Rs.182 crores invested in the quarter and Rs.385 crores in H1 FY24.
→CAPEX is mostly funded internally as no details about fresh fundraises via debt or equity were disclosed.
→Management indicated focus on cautious investment and strong capital deployment for future growth, but no intention or plan for raising new funds through debt or equity was shared.
→The company highlighted ongoing capacity expansions and project investments backed by operational cash flows and strategic funding but refrained from providing any guidance on fundraising activities.

Order book

Yes

→Laurus Labs currently has 62 active projects in its CDMO pipeline.
→Out of these, 10 projects are commercial products (including APIs and advanced intermediates).
→The remaining 60 projects are at various clinical stages (Phase II, Phase III).
→The company mentioned a strong order book for H2 FY24, especially in the oncology API segment.
→New CMO orders have been tied up and are expected to start ramping up, mainly in the second half of the fiscal year.
→CDMO capacity expansions (including a new Unit-7 for CDMO) are ongoing to support increased order fulfillment.
→The company is optimistic about order book growth and revenue improvement once the new capacities are fully utilized.

Capex plans

Yes

→Ongoing CAPEX of $100 million in synthesis expected to be reasonably utilized by mid of next financial year (FY25).
→Majority of FY24 CAPEX focused on synthesis and bio divisions, with expansion projects on track to support future growth.
→New capacity additions include 3 million liters of capacity and 5 billion tablets capacity in last three years.
→Groundbreaking of Unit-7 in Vizag to add more capacity for CDMO with common infrastructure.
→Creating common infrastructure and additional blocks at two sites to get regulatory approvals for servicing big pharma.
→ImmunoACT is creating a facility ready by March 2025 to deliver additional 2,500 treatments per year.
→Additional details on new CAPEX in new sites to be shared in the next quarter conference call.

How does Laurus Labs Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1Laurus Labs Ltd

Rev 3Mar 1

See full Pharmaceuticals & Biotechnology sector rankings

Want more stocks like Laurus Labs Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio